secwatch.observer — SEC 8-K summary
======================================

Issuer:     Viridian Therapeutics, Inc.\DE (VRDN)
CIK:        0001590750
Form:       8-K
Filed at:   2026-05-05T23:59:59+00:00
Accession:  0001193125-26-205010
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Viridian Q1 net loss $104.9M; veligrotug PDUFA June 30, elegrobart positive data, BLA Q1 2027
--------------------------------------------------------------------------------

- Cash $762.2M at March 31, 2026, down from $874.7M at Dec 31, 2025; net loss $104.9M vs $86.9M YoY.
- Veligrotug BLA under Priority Review with PDUFA target June 30, 2026; launch-ready with hired field teams.
- Elegrobart (subcutaneous) met primary endpoints in REVEAL-1 (active TED) and REVEAL-2 (chronic TED); proptosis responder rates 50-63% vs 15-18% placebo.
- BLA for elegrobart expected Q1 2027; MAA for veligrotug submitted to EMA and accepted for review.
- SG&A jumped to $38.7M from $17.1M due to commercial prep; R&D flat at $77.6M.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1590750/000119312526205010/0001193125-26-205010-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1590750/000119312526205010/d149508d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-205010

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer